Ketorolac Tromethamine 0.5 Per Cent in Vernal Kerato
conjunctivitis
PANIDA KOSRIRUKVONGS, MD*,
CHAINARONG LUENGCHAICHA W ANGE, MD*
Affiliation : *Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
AbstractA Prospective, randomized cross-over study was conducted in patients with vernal kerato
conjunctivitis, successfully treated with cyclosporine, to evaluate the efficacy of cyclosporine 0.5 per
cent compared with preservative-free ketorolac tromethamine 0.5 per cent. Patients received topical
cyclosporine in both eyes along with an assessment of the severity of their conjunctivitis. In cyclo
sporine-treated patients, medication was discontinued 1 week before evaluation, then the medication
was started for 1 month, and washed out 1 week before the other drug was started. Symptoms of itch
ing, foreign body sensation, tearing, photophobia, discharge, burning, conjunctival injection, chemosis,
giant papilla, keratopathy and intraocular pressure were evaluated weekly. There was a statistically
significant decrease in all symptoms of cyclosporine-treated eyes at day 7, 14 and 30 and all signs at
day 21 and 30. In ketorolac-treated eyes, there was a significant difference in itching, foreign body
sensation, photophobia, tearing, mucous discharge, all symptoms, chemosis, giant papillae and con
junctival injection at day 7, and overall symptoms at day 14. Compared to cyclosporine- treated eyes
at day 7, kotorolac-treated eyes had significantly fewer symptoms. Topical cyclosporine 0.5 per cent
reduces symptoms and signs slower than preservative-free ketorolac tromethamine 0.5 per cent.
Keywords : Vernal Keratoconjunctivitis, Topical Cyclosporine, Ketorolac Tromethamine
All Articles
Download
